NEW YORK (GenomeWeb) – The US Food and Drug Administration has cleared an assay on Quidel's Solana platform to detect and differentiate herpes simplex viruses types 1 and 2 and varicella-zoster virus.

The test does not require upfront DNA extraction, detecting HSV-1, HSV-2, and VZV DNA in cutaneous or mucocutaneous lesion samples from symptomatic patients, including specimens collected in transport media. The Solana platform employs the firm's helicase-dependent amplification technology, and processes up to 12 samples per run, with run time of about one-hour.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.